SG11201700157VA - Purification platform for bispecific antibodies - Google Patents
Purification platform for bispecific antibodiesInfo
- Publication number
- SG11201700157VA SG11201700157VA SG11201700157VA SG11201700157VA SG11201700157VA SG 11201700157V A SG11201700157V A SG 11201700157VA SG 11201700157V A SG11201700157V A SG 11201700157VA SG 11201700157V A SG11201700157V A SG 11201700157VA SG 11201700157V A SG11201700157V A SG 11201700157VA
- Authority
- SG
- Singapore
- Prior art keywords
- bispecific antibodies
- purification platform
- purification
- platform
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/26—Cation exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029463P | 2014-07-26 | 2014-07-26 | |
| PCT/US2015/041936 WO2016018740A2 (fr) | 2014-07-26 | 2015-07-24 | Plate-forme de purification pour anticorps bispécifiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700157VA true SG11201700157VA (en) | 2017-02-27 |
Family
ID=53836215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900661YA SG10201900661YA (en) | 2014-07-26 | 2015-07-24 | Purification platform for bispecific antibodies |
| SG11201700157VA SG11201700157VA (en) | 2014-07-26 | 2015-07-24 | Purification platform for bispecific antibodies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900661YA SG10201900661YA (en) | 2014-07-26 | 2015-07-24 | Purification platform for bispecific antibodies |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10626142B2 (fr) |
| EP (2) | EP3912987B9 (fr) |
| JP (1) | JP6702967B2 (fr) |
| KR (1) | KR102440737B1 (fr) |
| CN (1) | CN107074906B (fr) |
| AR (1) | AR101262A1 (fr) |
| AU (1) | AU2015298156B2 (fr) |
| CA (1) | CA2955618A1 (fr) |
| DK (2) | DK3172221T3 (fr) |
| EA (1) | EA036154B1 (fr) |
| ES (2) | ES2881026T3 (fr) |
| FI (1) | FI3912987T3 (fr) |
| IL (1) | IL255198B (fr) |
| MX (1) | MX2017001217A (fr) |
| MY (1) | MY187051A (fr) |
| PL (2) | PL3912987T3 (fr) |
| SG (2) | SG10201900661YA (fr) |
| TW (1) | TWI704155B (fr) |
| WO (1) | WO2016018740A2 (fr) |
| ZA (1) | ZA201700622B (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| PH12018501459A1 (en) | 2007-09-26 | 2019-11-11 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
| RU2663123C2 (ru) | 2010-11-30 | 2018-08-01 | Чугаи Сейяку Кабусики Кайся | Индуцирующий цитотоксичность терапевтический агент |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2016159213A1 (fr) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | Procédé pour la production d'un hétéro-oligomère polypeptidique |
| EP3549606A1 (fr) * | 2015-05-28 | 2019-10-09 | Bio-rad Laboratories, Inc. | Ligands d'affinité et procédés associés |
| KR20180091918A (ko) * | 2015-12-28 | 2018-08-16 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법 |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2017194592A1 (fr) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Procédé de conservation d'une matrice de séparation |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| AR108800A1 (es) * | 2016-06-17 | 2018-09-26 | Genentech Inc | Purificación de anticuerpos multiespecíficos |
| WO2018038469A1 (fr) * | 2016-08-20 | 2018-03-01 | (주)아이벤트러스 | Procédé de confirmation de production sélective d'anticorps bispécifique souhaité |
| KR101933656B1 (ko) | 2016-08-20 | 2018-12-28 | (주) 아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| CN111902720A (zh) | 2018-03-21 | 2020-11-06 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| GB201805142D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| EP3837552A1 (fr) | 2018-08-17 | 2021-06-23 | Regeneron Pharmaceuticals, Inc. | Procédé et système de chromatographie permettant la détermination de la quantité et de la pureté d'une protéine multimère |
| JPWO2020066270A1 (ja) * | 2018-09-28 | 2021-08-30 | 株式会社カネカ | κ鎖可変領域を含む抗体および／または抗体断片の製造方法 |
| KR20210111243A (ko) | 2018-10-31 | 2021-09-10 | 리제너론 파아마슈티컬스, 인크. | 단백질을 식별 및 정량화하는 방법 및 시스템 |
| CA3110377A1 (fr) * | 2018-11-21 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-staphylococcus et leurs utilisations |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| JP2024504880A (ja) | 2018-12-24 | 2024-02-02 | サノフイ | 疑似ｆａｂベースの多重特異性結合タンパク質 |
| KR20220019755A (ko) | 2019-06-11 | 2022-02-17 | 리제너론 파마슈티칼스 인코포레이티드 | PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법 |
| EA202290040A1 (ru) * | 2019-06-13 | 2022-03-05 | Ридженерон Фармасьютикалз, Инк. | Способы удаления нежелательных компонентов в многостадийных хроматографических процессах |
| TW202128744A (zh) | 2019-12-06 | 2021-08-01 | 美商再生元醫藥公司 | 抗ｖｅｇｆ蛋白組合物及其製備方法 |
| BR112022011993A2 (pt) * | 2019-12-26 | 2022-09-20 | Abl Bio Inc | Método para purificar peptídeo biologicamente ativo usando cromatografia de afinidade de proteína a |
| KR20210084054A (ko) | 2019-12-27 | 2021-07-07 | 케이에스광학주식회사 | 투명한 방탄 적층 구조물 |
| KR20220107968A (ko) * | 2021-01-25 | 2022-08-02 | 주식회사유한양행 | 항-4-1bb/항-her2 이중특이적 항체의 정제방법 |
| GB202109246D0 (en) * | 2021-06-28 | 2021-08-11 | Cytiva Bioprocess R & D Ab | A method of separating bispecific antibodies |
| AU2022369694A1 (en) * | 2021-10-19 | 2024-05-30 | Alteogen, Inc | Method for purifying fusion protein having igg fc domain |
| WO2023247468A2 (fr) * | 2022-06-22 | 2023-12-28 | Puridify Limited | Matrice de convection de liaison à une chaîne légère kappa |
| WO2024123698A1 (fr) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Procédés pour caractériser un domaine fragment cristallisable d'un anticorps bispécifique |
| CN116769044A (zh) * | 2023-07-11 | 2023-09-19 | 康日百奥生物科技(苏州)有限公司 | 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8626413D0 (en) | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2176574T3 (es) | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
| ES2169299T3 (es) | 1996-09-03 | 2002-07-01 | Gsf Forschungszentrum Umwelt | Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos. |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| US6994853B1 (en) | 1998-09-25 | 2006-02-07 | Trion Pharma Gmbh | Time-staggered utilization of tumor cells in combination with intact antibodies for immunization |
| US20030224000A1 (en) | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| US7169903B2 (en) | 2001-12-21 | 2007-01-30 | Biosynexus Incorporated | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| CA2872136C (fr) | 2002-07-18 | 2017-06-20 | Merus B.V. | Production par recombinaison de melanges d'anticorps |
| CN104926938B (zh) | 2005-06-17 | 2019-06-04 | 惠氏有限责任公司 | 纯化含Fc区蛋白的方法 |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| SG149759A1 (en) * | 2007-07-10 | 2009-02-27 | Millipore Corp | Media for affinity chromatography |
| WO2010030222A1 (fr) * | 2008-09-12 | 2010-03-18 | Ge Healthcare Bio-Sciences Ab | Séparation protéine-agrégat améliorée avec des échangeurs d'anions multimodaux en présence de zwitterions exclus de la protéine |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
| MX2012007497A (es) * | 2009-12-25 | 2012-08-01 | Chugai Pharmaceutical Co Ltd | Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido. |
| RU2663123C2 (ru) * | 2010-11-30 | 2018-08-01 | Чугаи Сейяку Кабусики Кайся | Индуцирующий цитотоксичность терапевтический агент |
| EP2500073A1 (fr) * | 2011-03-17 | 2012-09-19 | ChromaCon AG | Procédé pour l'identification et la purification de polypeptides plurispécifiques |
| AU2013234039B2 (en) * | 2012-03-13 | 2018-02-01 | Novimmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| KR20150076172A (ko) * | 2012-09-25 | 2015-07-06 | 그렌마크 파머수티칼스 에스. 아. | 이질-이합체 면역글로불린의 정제 |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
-
2015
- 2015-07-21 AR ARP150102301A patent/AR101262A1/es unknown
- 2015-07-23 TW TW104123813A patent/TWI704155B/zh active
- 2015-07-24 EA EA201790247A patent/EA036154B1/ru not_active IP Right Cessation
- 2015-07-24 SG SG10201900661YA patent/SG10201900661YA/en unknown
- 2015-07-24 ES ES15750182T patent/ES2881026T3/es active Active
- 2015-07-24 EP EP21170436.6A patent/EP3912987B9/fr active Active
- 2015-07-24 CN CN201580040494.9A patent/CN107074906B/zh active Active
- 2015-07-24 CA CA2955618A patent/CA2955618A1/fr active Pending
- 2015-07-24 MY MYPI2017700080A patent/MY187051A/en unknown
- 2015-07-24 PL PL21170436.6T patent/PL3912987T3/pl unknown
- 2015-07-24 EP EP15750182.6A patent/EP3172221B1/fr active Active
- 2015-07-24 US US14/808,171 patent/US10626142B2/en active Active
- 2015-07-24 SG SG11201700157VA patent/SG11201700157VA/en unknown
- 2015-07-24 JP JP2017525320A patent/JP6702967B2/ja active Active
- 2015-07-24 WO PCT/US2015/041936 patent/WO2016018740A2/fr active Application Filing
- 2015-07-24 AU AU2015298156A patent/AU2015298156B2/en active Active
- 2015-07-24 MX MX2017001217A patent/MX2017001217A/es active IP Right Grant
- 2015-07-24 FI FIEP21170436.6T patent/FI3912987T3/fi active
- 2015-07-24 ES ES21170436T patent/ES2942533T3/es active Active
- 2015-07-24 PL PL15750182T patent/PL3172221T3/pl unknown
- 2015-07-24 DK DK15750182.6T patent/DK3172221T3/da active
- 2015-07-24 DK DK21170436.6T patent/DK3912987T3/da active
- 2015-07-24 KR KR1020177003803A patent/KR102440737B1/ko active IP Right Grant
-
2017
- 2017-01-25 ZA ZA2017/00622A patent/ZA201700622B/en unknown
- 2017-10-22 IL IL255198A patent/IL255198B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255198A0 (en) | A purification platform for bispecific antibodies | |
| IL282403B1 (en) | Antibodies against pd-1 | |
| HK1232127A1 (zh) | 雙特異性 抗體 | |
| IL251963A0 (en) | Anti-1-pd antibodies | |
| IL250583A0 (en) | Anti-tigit antibodies | |
| PL3130606T3 (pl) | Przeciwciała dwuswoiste aktywujące układ odpornościowy | |
| HK1245804A1 (zh) | 用於治療pvns的抗csf1r抗體 | |
| IL265016B (en) | A method for purifying antibodies | |
| EP3143154A4 (fr) | Anticorps bispécifiques bloqués chimiquement | |
| IL250374B (en) | Antibodies against ceramide | |
| IL248697A0 (en) | Methods for purifying antibodies | |
| SG11201607098SA (en) | Antibody purification process | |
| HK1250046A1 (zh) | 抗dkk-1-抗rankl雙特異性抗體化合物 | |
| HK1243993A1 (zh) | 液體淨化系統 | |
| ZA201704704B (en) | Antibodies for il-17c | |
| SG11201610594WA (en) | Anti-il4-il 13 bispecific antibodies | |
| SG11201704540YA (en) | Method for purifying easily polymerizable substance | |
| IL272676B (en) | Bispecific antibodies against il-4 and il-13 | |
| GB201419080D0 (en) | Anti-PD-1 antibodies | |
| GB201419087D0 (en) | Anti-PD-1 antibodies | |
| GB201419092D0 (en) | Anti-TIM-3 antibodies | |
| GB201419089D0 (en) | Anti-TIM-3 antibodies | |
| GB201417614D0 (en) | Antibodies | |
| GB201414270D0 (en) | Antibodies | |
| GB201405775D0 (en) | Antibodies |